Group One Trading
OCUL icon

Group One Trading’s Ocular Therapeutix OCUL Stock Holding History

Group One Trading’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.62M Sell
191,800
-181,600
-49% -$1.73M ﹤0.01% 2263
2025
Q4 		$4.53M Buy
373,400
+33,800
+10% +$411K 0.01% 1591
2025
Q3 		$3.97M Buy
339,600
+101,100
+42% +$1.21M 0.01% 1689
2025
Q2 		$2.21M Sell
238,500
-33,700
-12% -$264K ﹤0.01% 2038
2025
Q1 		$2M Buy
272,200
+125,800
+86% +$967K 0.01% 1806
2024
Q4 		$1.25M Buy
146,400
+48,200
+49% +$470K ﹤0.01% 2349
2024
Q3 		$854K Sell
98,200
-34,200
-26% -$282K ﹤0.01% 2439
2024
Q2 		$906K Sell
132,400
-1,400
-1% -$8.64K ﹤0.01% 2069
2024
Q1 		$1.22M Buy
133,800
+53,400
+66% +$379K ﹤0.01% 1911
2023
Q4 		$359K Sell
80,400
-23,600
-23% -$69.8K ﹤0.01% 3347
2023
Q3 		$327K Sell
104,000
-169,400
-62% -$693K ﹤0.01% 3350
2023
Q2 		$1.41M Buy
273,400
+215,600
+373% +$1.28M ﹤0.01% 2025
2023
Q1 		$305K Buy
57,800
+57,300
+11,460% +$272K ﹤0.01% 3259
2022
Q4 		$1.41K Sell
500
-400
-44% -$1.32K ﹤0.01% 6754
2022
Q3 		$4K Buy
+900
New +$4.53K ﹤0.01% 6943
2022
Q2 		– Sell
-1,300
Closed -$6K – 8290
2022
Q1 		$6K Sell
1,300
-12,200
-90% -$67.6K ﹤0.01% 7386
2021
Q4 		$94K Sell
13,500
-76,300
-85% -$593K ﹤0.01% 5782
2021
Q3 		$898K Sell
89,800
-33,700
-27% -$378K ﹤0.01% 3536
2021
Q2 		$1.75M Buy
123,500
+81,300
+193% +$1.24M ﹤0.01% 2807
2021
Q1 		$693K Buy
42,200
+16,700
+65% +$322K ﹤0.01% 3661
2020
Q4 		$528K Buy
25,500
+2,400
+10% +$35.6K ﹤0.01% 3212
2020
Q3 		$176K Sell
23,100
-84,300
-78% -$700K ﹤0.01% 3752
2020
Q2 		$895K Buy
107,400
+20,200
+23% +$134K ﹤0.01% 2130
2020
Q1 		$432K Sell
87,200
-21,000
-19% -$104K ﹤0.01% 2152
2019
Q4 		$427K Buy
108,200
+62,000
+134% +$216K ﹤0.01% 2563
2019
Q3 		$140K Sell
46,200
-63,400
-58% -$283K ﹤0.01% 3340
2019
Q2 		$482K Buy
109,600
+21,100
+24% +$78.1K ﹤0.01% 2167
2019
Q1 		$351K Buy
88,500
+73,700
+498% +$296K ﹤0.01% 2238
2018
Q4 		$59K Sell
14,800
-2,600
-15% -$14.3K ﹤0.01% 3467
2018
Q3 		$120K Sell
17,400
-41,400
-70% -$260K ﹤0.01% 3396
2018
Q2 		$397K Buy
58,800
+16,700
+40% +$115K ﹤0.01% 2489
2018
Q1 		$274K Buy
42,100
+23,400
+125% +$132K ﹤0.01% 2544
2017
Q4 		$83K Sell
18,700
-30,600
-62% -$156K ﹤0.01% 3463
2017
Q3 		$305K Buy
49,300
+35,200
+250% +$227K ﹤0.01% 2458
2017
Q2 		$131K Sell
14,100
-7,600
-35% -$73.6K ﹤0.01% 2945
2017
Q1 		$201K Buy
21,700
+700
+3% +$5.83K ﹤0.01% 2516
2016
Q4 		$176K Buy
21,000
+16,400
+357% +$127K ﹤0.01% 2505
2016
Q3 		$32K Sell
4,600
-1,800
-28% -$11K ﹤0.01% 3584
2016
Q2 		$32K Buy
6,400
+2,600
+68% +$25.8K ﹤0.01% 3563
2016
Q1 		$37K Hold
3,800
– – ﹤0.01% 3428
2015
Q4 		$36K Sell
3,800
-2,200
-37% -$23.8K ﹤0.01% 3607
2015
Q3 		$84K Buy
+6,000
New +$121K ﹤0.01% 3168

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Group One Trading's OCUL Position: Q3 2025 in Review

Group One Trading sold out of Ocular Therapeutix (OCUL) in Q3 2025, closing a stake of 11,950 shares — an estimated $143K sold.

Group One Trading first reported a position in OCUL in Q3 2015 and held it in 27 quarters. The position peaked at $3.4M in Q1 2024. 216 funds tracked by Wall St. Rank hold OCUL as of Q3 2025.

  • Group One Trading reported no remaining Ocular Therapeutix position as of Q3 2025 after selling out during the quarter.
  • Group One Trading sold 11,950 Ocular Therapeutix shares in Q3 2025, an estimated $143K.
  • Group One Trading first reported a position in Ocular Therapeutix in Q3 2015 and held it in 27 quarters.
  • Group One Trading's Ocular Therapeutix position peaked at $3.4M in Q1 2024.
  • 216 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2025.

Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.